Table 2.
Mutation-specific response to FLT3 inhibitors: Fold change in IC50 compared to FLT3-ITD.
| FLT3-Mut | Midostaurin | Sorafenib | Sunitinib | Lestaurtinib | Tandutinib | Quizartinib | Crenolanib | Gilteritinib |
|---|---|---|---|---|---|---|---|---|
| FLT3-ITD | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| D835Y | −3.00 | 190.91 | 7.22 | 1.14 | >18.18 | 73.33 | −1.72 | −1.13 |
| D835V | −3.73 | - | 13.75 | - | >18.18 | 19.11 | −3.14 | - |
| ITD-D835Y | 7.33 | 3000.00 | 31.67 | −1.11 | - | 1000.00 | 1.53 | 1.17 |
| ITD-D835V | 1.08 | 780.94 | 3.25 | - | - | 468.42 | 1.44 | - |
Yellow indicates mutations showing no difference in sensitivity to TKIs compared to ITD mutations. Green indicate that mutations are more sensitive to TKI than ITD mutations. Red indicate mutations which are more resistant to TKIs than ITD mutations. All studies utilized Ba/F3 cell lines; however, methods of IC50 determination differed by study. Table created using data from references [31,143,146,149,152,153,154,155,156].